Lv2
138 积分 2024-07-24 加入
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing
1个月前
已完结
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
2个月前
已完结
Isolated Cubital Node Metastasis in a Treated Case of Breast Carcinoma on 18 F-FDG PET/CT: A Rare Finding
3个月前
已关闭
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
4个月前
已完结
Second-Line Treatment Options in Non–Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology
6个月前
已完结
HER2 in gynecological malignancies: Bridging the gap between standardized pathological assessment and precision therapy
6个月前
已关闭
[Chinese clinical practice guideline for genetic testing in advanced breast cancer (2025 edition)]
7个月前
已完结
Next-generation sequencing for PTEN testing in HR+/HER2˗ metastatic breast cancer
7个月前
已完结
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
7个月前
已完结
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial
7个月前
已完结
皖公网安备34019202002308
